Bold Stocks | Hot Stock Picks

MDMC

America`s Top Micro-Cap Stock Authority Reveals This Stunning Secret:

AS SEEN ON:

Facebook`s NEXT Buyout… It`s A Move That Could Push This Startup`s Shares As Much As 2,700% Higher! An immediate wealth-building opportunity for investors seeking ground-floor entry into the next Super Trend

Dear Opportunistic Investor: People who are drooling over Facebook`s coming IPO have their eyes on the wrong prize. Instead, they should be looking at a small startup company that I have just uncovered. I`m now convinced Facebook must buy out this startup for as much as $1 billion. This could create a monumental payoff for ground-floor investors. After spending months making sure my research stands up, I have published all the details in a new report. It contains my in-depth coverage of this startup… and the Mega Trend it is riding. But, because this trend is so hot, I don`t believe this startup company`s shares, below $1, will stay at a ground-floor price much longer. In fact, MDMC has just rolled out a nationwide venture that I believe could send its shares to $3 or beyond – even before a potential Facebook buyout. My report details how this company has something Facebook desperately needs.

A Trusted Authority When America`s most respected business journalists want to get it right, they call John Person for his market opinions. Widely quoted by CBS Market Watch, Reuters, Dow Jones Newswires, he appears regularly on CNBC as well. John is also a sought after speaker for many professional organizations such as the Market Technicians Association, the International Federation of Technical Analyst Society. He also delivers keynote speeches and seminars at some of the countries top national investment expos.

So, my strongest advice to you is this… Avoid the Facebook IPO at all costs! Instead, go hunting for gains that could exceed 2,700%. Pour your efforts into the startup that I believe Facebook must buy out for as much as $1 billion. Now, quickly, here`s what`s going on… the complete details are in my new special report. Playing Catch Up Is Costly For Facebook… But It Could Mean Your Biggest Payday Ever! Though it may seem hard to believe there`s a huge weakness in Facebook`s business strategy… and management knows it. I`ll show you how Facebook described the problem in its pre-IPO Securities and Exchange Commission filing. It`s all about how Facebook needs to quickly alter its game plan or get left way behind on a huge profit-making Mega Trend. The only way I can imagine it swiftly making up this lost ground is via an acquisition… Buying out a company (MDMC) that has the breakthrough technology Facebook needs today. Facebook Must Act Fast… And You Must Act Now! The company I am convinced Facebook needs to buy now is Marine Drive Mobile (MDMC). As I said, MDMC is a startup that has something Facebook desperately needs… the instant ability to tap into the world`s newest Mega Trend . MDMC is the solution to Facebook`s biggest problem. Best of all, because MDMC is a startup company, most investors haven`t learned of it yet… you`re one of the first… so, MDMC still trades for below $1. I urge you now to set aside what you are doing and read my complete report. Follow the link below. Then be ready to call your broker. And, even if you`re not interested in startup investments, please read my Special Report anyway… that way you`ll know about the Mega Trend and how it could lead you to effortless millions. But, if you`re someone who knows how startups can reward ground-floor investors with untold fortunes… Don`t wait. Don`t get left behind. Facebook could move fast! Could MDMC Jump From Below $1 Past $27 On A Facebook Buyout

Here`s to your success.

John Person

PS I just published this Special Report on MDMC and you`re among the first to see it. So don`t hesitate, be sure to act on it before all of Wall Street picks up on the information it reveals.

Disclosure: Pentony Enterprises LLC entered into an awareness agreement for coverage of MDMC this week. A non-controlling third party has agreed to compensate four thousand six hundred dollars for coverage of MDMC. We have no shares of the company`s stock, nor will we buy, sell or otherwise be trading any shares at anytime during this awareness campaign. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. Our contact information is Pentony Enterprises; 1601 Berwick Drive; McKinney, Texas 75070; Telephone 469-252-3030.

MDMC

Your email client cannot read this email.

To view it online, please go here:

http://www.sgurunews.com/emailmarketer/display.phpM643&C=df5bfe90bb388ac23100d51cdcde5552&S02&L=5&N48 Paid Advertising – Pentony Enterprises LLC “PE” The report and content of this presentation is a paid advertisement. It was paid for by a non-controlling third party for dissemination of this copy. We have taken no shares. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. We hold no shares and will not be receiving further compensation in shares or that is share related during this period. Total compensation from the third party for sending this is thirty three hundred dollars. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. As advertising, PE was hired for the distribution of the attached content. PE did not author or endorse the content, and as a rule never does when hired for advertising. Paid Advertising – Pentony Enterprises LLC 1601 Berwick Drive McKinney, Texas 75070 (469) 252-3031.

To stop receiving these emails:http://www.sgurunews.com/emailmarketer/

No tags

Your email client cannot read this email.

To view it online, please go here:

http://www.sgurunews.com/emailmarketer/display.phpM596&C=c7c822f09eefcb0dac0453b7afd60b76&S57&L=3&N88 Having trouble reading this email View it in your browser.

a Vicor Technologies, Inc.

[vcrt-midday-MEDIUM] VCRT Continues its Climb – Now Up 105% Since our Shareholder Vision Video Last Monday Big Week Last Week for VCRT as it Moves Upward 88% from Monday Low to Friday Close – now up 105% and rising! Monday saw a low of $0.085.

Today – so far – at: $0.175 See the video here:

Shareholder Vision Releases New Video Interview with David Fater of Vicor Technologies, Inc.

To view the video interview, please visit:

http://www.sgurunews.com/emailmarketer/link.phpM596&N57&L03&F=T June 21, 2011 Dallas, Texas: John Pentony, Publisher of ShareholderVision.com, announced today that Shareholder Vision has released a new video interview featuring David Fater, President and Chief Executive Officer of Vicor Technologies, Inc. (OTCBB: VCRT). The interview was recorded recently in Boca Raton, Florida, the headquarters for Vicor Technologies, Inc. Shareholder Vision presents an exceptional look at an outstanding company, a CEO with world class experience in his field, and a bio-tech company that is now capitalizing on over a decade of patented work.

Vicor Technologies is a biotechnology company focused on the commercialization of its PD2i Analyzer, an innovative, non-invasive diagnostic employing its patented, proprietary PD2i nonlinear algorithm.

Physician use of the PD2i Analyzer is supported by an expanding body of literature documenting the PD2i nonlinear algorithm as a metric for risk stratifying specific target populations for future pathological events, including diabetics for the presence of diabetic autonomic neuropathy (DAN), cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, and trauma victims for imminent death absent immediate lifesaving intervention. Vicor is actively transforming itself from a development-stage biotechnology company into a fully-realized commercial venture with a national sales force and international distribution. Physicians are using Vicors PD2i Analyzer to identify autonomic nervous system, also known as diabetic autonomic neuropathy (DAN), in their patients with diabetes, and to identify those among their patients with cardiovascular disease at risk for death resulting from arrhythmia or congestive heart failure. Current procedural terminology (CPT) codes enable physicians using the PD2i Analyzer as a measure of heart rate variability to be reimbursed by insurance carriers, creating a recurring source of revenue from test analysis for Vicor. In April, Vicor received 510(k) marketing clearance from the U.S. Food and Drug Administration for its PD2i Analyzer to be used as a measure of heart rate variability at rest, and in response to controlled exercise and paced respiration (Ewing Maneuvers) in patients specifically undergoing cardiovascular disease testing. Sixty published manuscripts of studies involving the use of Vicors PD2i nonlinear algorithm attest to its ability to identify and predict a wide variety of medical disorders and conditions.

To view the video interview, please visit:

http://www.sgurunews.com/emailmarketer/link.phpM596&N57&L03&F=T StockGuru`s Profile for Vicor Technologies, Inc.

This is the condensed version – Full StockGuru Profile Found Here:

http://www.sgurunews.com/emailmarketer/link.phpM596&N57&L69&F=T Vicor Technologies, Inc. (OTCBB: VCRT) is a medical diagnostics company focused on commercializing noninvasive diagnostic technology products based on its patented, proprietary point correlation dimension algorithm the PD2i Algorithm and software.

With the second FDA approval under its belt in April, Vicor is fully in the process of transforming itself into a commercial company with a national sales force and international reach.

The Company has all of the regulatory approvals in place already with regards to PD2i to generate substantial revenues.

FDA Approval of PD2i Analyzer for BOTH Heart Rate Variability and Cardiovascular Disease Testing Vicors PD2i Analyzer has FDA 510(k) marketing clearance to both:

Measure heart rate variability (HRV) for physician-determined use which can assess autonomic nervous system dysfunction in diabetics.

And be used specifically in patients undergoing cardiovascular disease testing.

Potential Market PD2i Analyzer The potential market for the PD2i Analyzer with 77 million potential patients could be in the multi-billions of dollars. This market is supported by the recent FDA approval to market the PD2i Analyzer for cardiovascular disease testing is anticipated to spur market acceptance of the PD2i Analyzer as a valuable new diagnostic.

The groundbreaking 510(k) obtained in April of 2011, for the use of the PD2i metric includes the classical Ewing maneuvers with the PD2i metric in patients undergoing cardiovascular disease testing.

This FDA Approval is an accomplishment of incredible significance for VCRT as both national and international acceptance begin to accelerate. This landmark approval has been sought since the first introduction of the PD2i technology by Vicor in 2003.

These populations are significant:

23.6 million diabetics 15 million at-risk cardiac patients 38 million trauma incidents PD2i Analyzer Provides Additional Revenue Source for Physicians and Improves Patient Care Physicians can now expect a higher return on investment with the April 2011 FDA 501(k) for cardiovascular disease testing.

Vicor is now able to broaden its marketing message and could significantly increase interest in the Analyzer particularly with cardiologists.

Physicians are able to use the Analyzer for indications believed to be useful. FDA clearance of specific indications allows Vicor to explicitly market for those indications.

Current procedural terminology (CPT) codes enable physicians using the PD2i Analyzer to be reimbursed by insurance carriers, creating a recurring source of revenue from test analysis for Vicor.

The PD2i Analyzer is used as a diagnostic for heart rate variability, which is a widely-accepted measure of autonomic nervous system health and by extension cardiac health.

The PD2i Algorithm facilitates the ability of physicians to accurately risk stratify a specific target population to predict future pathological events such as autonomic nervous system dysfunction, cardiac mortality (either from arrhythmic death or congestive heart failure) and imminent death from trauma.

PD2i Algorithm New and Accurate Vital Sign The Company believes that the PD2i Algorithm represents a noninvasive monitoring technology that physicians and other members of the medical community can use as a new and accurate vital sign.

Two proprietary diagnostic medical products are being commercialized which employ software utilizing the PD2i Algorithm:

First – the PD2i Analyzer Second – the PD2i Cardiac Analyzer The PD2i VS Vital Sign Monitor for trauma, triage, and other hospital uses in still under development.

FDA Clearance In April 2011 the Company received 510(k) clearance from the U.S. Food and Drug Administration for its PD2i nonlinear algorithm and software to be used as a measure of heart rate variability at rest and in response to controlled exercise and paced respiration (Ewing Maneuvers) in patients specifically undergoing cardiovascular disease testing.

Physician use of the PD2i Analyzer is supported by an expanding body of literature demonstrating the value of the PD2i nonlinear algorithm as a metric for risk stratifying specific target populations for future pathological events.

This is the condensed version – Full StockGuru Profile Found Here:

http://www.sgurunews.com/emailmarketer/link.phpM596&N57&L69&F=T Contact Vicor Technologies, Inc.

David H. Fater, CEO Vicor Technologies, Inc.

561.995.7313 dfater@vicortech.com ..

a Vicor Technologies North Bay Resources VIASPACE, Inc.

Vuzix Corporation Mantra Venture Group Princeton Security Technologies Next 1 Interactive AtheroNovaAbout StockGuru:

The original service that has become StockGuru started in the late `90`s.

At first if was our publisher sharing picks with his friends. Then it grew.

Then it became a formal list in 2001. In 2002 it became a web site. In 2003 it became StockGuru. READ ALL ABOUT IT HERE.

..

Contact StockGuru:

P: 469-358-5200 F: 214-975-1238 Publisher@StockGuru.com This message was intended for “ You have received this message because you are subscribed to `Bold Stocks Alerts` VCRT Disclosure: Pentony Enterprises LLC entered into an investor relations consulting and market awareness contract with VCRT. We are also doing a video on ShareholderVision.com that will be released shortly. The Company will pay us a total of seventy two hundred dollars and fifty thousand shares of restricted 144 stock for the period ending August 31, 2011. We still hold hold these shares. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In early 2010, the Company paid us seventy two hundred dollars and fifty thousand shares of restricted 144 stock for a prior round of coverage that ended. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. Pentony Enterprises LLC 1601 Berwick Drive McKinney, Texas 75070 (469) 252-3031.

VCRT

Your email client cannot read this email.

To view it online, please go here:

http://www.sgurunews.com/emailmarketer/display.phpM596&C=c7c822f09eefcb0dac0453b7afd60b76&S49&L=3&N79 Shareholder Vision Releases New Video Interview with David Fater of Vicor Technologies, Inc.

Having trouble reading this email View it in your browser.

a Vicor Technologies, Inc.

Shareholder Vision Releases New Video Interview with David Fater of Vicor Technologies, Inc.

June 21, 2011 Dallas, Texas: John Pentony, Publisher of ShareholderVision.com, announced today that Shareholder Vision has released a new video interview featuring David Fater, President and Chief Executive Officer of Vicor Technologies, Inc. (OTCBB: VCRT). The interview was recorded recently in Boca Raton, Florida, the headquarters for Vicor Technologies, Inc. Shareholder Vision presents an exceptional look at an outstanding company, a CEO with world class experience in his field, and a bio-tech company that is now capitalizing on over a decade of patented work.

Vicor Technologies is a biotechnology company focused on the commercialization of its PD2i Analyzer, an innovative, non-invasive diagnostic employing its patented, proprietary PD2i nonlinear algorithm.

Physician use of the PD2i Analyzer is supported by an expanding body of literature documenting the PD2i nonlinear algorithm as a metric for risk stratifying specific target populations for future pathological events, including diabetics for the presence of diabetic autonomic neuropathy (DAN), cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, and trauma victims for imminent death absent immediate lifesaving intervention.

Vicor is actively transforming itself from a development-stage biotechnology company into a fully-realized commercial venture with a national sales force and international distribution. Physicians are using Vicors PD2i Analyzer to identify autonomic nervous system, also known as diabetic autonomic neuropathy (DAN), in their patients with diabetes, and to identify those among their patients with cardiovascular disease at risk for death resulting from arrhythmia or congestive heart failure.

Current procedural terminology (CPT) codes enable physicians using the PD2i Analyzer as a measure of heart rate variability to be reimbursed by insurance carriers, creating a recurring source of revenue from test analysis for Vicor. In April, Vicor received 510(k) marketing clearance from the U.S. Food and Drug Administration for its PD2i Analyzer to be used as a measure of heart rate variability at rest, and in response to controlled exercise and paced respiration (Ewing Maneuvers) in patients specifically undergoing cardiovascular disease testing.

Sixty published manuscripts of studies involving the use of Vicors PD2i nonlinear algorithm attest to its ability to identify and predict a wide variety of medical disorders and conditions.

To view the video interview, please visit:

http://www.sgurunews.com/emailmarketer/link.phpM596&N49&L00&F=T Vicor Technologies, Inc. (OTCBB: VCRT) Disclosure: Pentony Enterprises LLC entered into an investor relations consulting and market awareness contract with VCRT. We are also doing a video on ShareholderVision.com that will be released shortly. The Company will pay us a total of seventy two hundred dollars and fifty thousand shares of restricted 144 stock for the period ending August 31, 2011. We still hold hold these shares. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In early 2010, the Company paid us seventy two hundred dollars and fifty thousand shares of restricted 144 stock for a prior round of coverage that ended. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. Pentony Enterprises LLC 1601 Berwick Drive McKinney, Texas 75070 (469) 252-3031.

Contact:

Shareholder Vision John Pentony, Publisher john@shareholdervision.com Tel: (469) 250-3030 StockGuru`s Profile for Vicor Technologies, Inc.

This is the condensed version – Full StockGuru Profile Found Here:

http://www.sgurunews.com/emailmarketer/link.phpM596&N49&L69&F=T Vicor Technologies, Inc. (OTCBB: VCRT) is a medical diagnostics company focused on commercializing noninvasive diagnostic technology products based on its patented, proprietary point correlation dimension algorithm the PD2i Algorithm and software.